Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

D. Rivera, S. Peters, O. Panagiotou, D. Shah, N. Kuderer, Chih-Yuan Hsu, S. Rubinstein, B. J. Lee, T. Choueiri, G. de Lima Lopes, P. Grivas, C. Painter, B. Rini, M. Thompson, Jonathan T Arcobello, Z. Bakouny, D. Doroshow, P. Egan, D. Farmakiotis, L. Fecher, C. Friese, M. Galsky, S. Goel, Shilpa Gupta, T. Halfdanarson, B. Halmos, J. Hawley, A. Khaki, Christopher A. Lemmon, Sanjay Mishra, A. Olszewski, N. Pennell, M. Puc, S. Revankar, L. Schapira, A. Schmidt, G. Schwartz, S. Shah, Julie T Wu, Z. Xie, Albert C Yeh, Huili Zhu, Y. Shyr, G. Lyman, J. Warner

Cancer discovery, 2020

In a large observational study in patients with COVID-19 and cancer, survival was not significantly influenced by receipt of COVID-19 treatments, except hydroxychloroquine plus any other treatment, which was associated with reduced survival.

Cited by 44 publications.

Field of study: Medicine

10.1158/2159-8290.CD-20-0941